Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph phase_4
1
33%
Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 4Post-market surveillance
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Other(2)

Detailed Status

unknown2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 41 (50.0%)
N/A1 (50.0%)

Trials by Status

recruiting133%
unknown267%

Recent Activity

1 active trials
Showing 3 of 3
recruiting

Good-first: B/F/TAF As First-line ART

NCT06619288
unknownphase_4

Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection

NCT04296695
unknownnot_applicable

Efficacy and Safety of Tenofovir Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral Therapy

NCT01844297

Clinical Trials (3)

Showing 3 of 3 trials
NCT06619288

Good-first: B/F/TAF As First-line ART

Recruiting
NCT04296695Phase 4

Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection

Unknown
NCT01844297Not Applicable

Efficacy and Safety of Tenofovir Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral Therapy

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3